Evidence brief
TB-500: Research evidence and Canadian regulatory context
This educational profile distinguishes laboratory and preclinical discussion from clinical conclusions. It does not provide a treatment, administration, dosing, sourcing, or product-quality recommendation.
Evidence maturity: limited human data specific to TB-500; preclinical discussion dominates.
Human evidence
The cited sports-medicine review reports that human orthopaedic data for thymosin-beta-4 and TB-500 are lacking. A lack of human orthopaedic data is not evidence of clinical benefit or safety.
Preclinical context
The review summarizes angiogenesis and tissue-repair observations in preclinical models. Those observations should be read as research context, not as proof of an outcome for a person, injury, or condition.
What remains unknown
Clear human indications, controlled clinical trials, reliable safety characterization, and evidence-based information on administration, frequency, or duration are not established by the cited review.
Human-evidence table
A structured reading aid, not a treatment or product decision tool.
| Evidence maturity | Human-study context | Interpretation limit |
|---|---|---|
| limited human data specific to TB-500; preclinical discussion dominates. | The cited sports-medicine review reports that human orthopaedic data for thymosin-beta-4 and TB-500 are lacking. A lack of human orthopaedic data is not evidence of clinical benefit or safety. | Clear human indications, controlled clinical trials, reliable safety characterization, and evidence-based information on administration, frequency, or duration are not established by the cited review. |
Canadian regulatory context
Health Canada’s public advisory describes general risks of unauthorized injectable peptide drugs. It does not establish a clinical use, product quality standard, or individualized safety conclusion for TB-500.
Evidence timeline
- 1
Early research: thymosin-beta-4 biology and preclinical questions
- 2
Human literature: limited and not specific to orthopaedic TB-500 outcomes
- 3
Current: controlled human outcome and safety gaps remain
Sources and maintenance
Sources are linked directly so readers can review the original material and its limitations.
- Injectable peptide therapy review (2026)
Narrative review describing the absence of human orthopaedic data for TB-4/TB-500.
- Health Canada public advisory
Official Canadian information on unauthorized injectable peptide drugs.